ACC together with AHA and other key healthcare organizations, has launched "Door to Balloon (D2B): An Alliance ...
Stents
This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents.Â
The FDA has cleared Boston Scientific’s NexStent Carotid Stent and Monorail Delivery System for use in patients with ...
Results from the Danish SORT-OUT II study, the largest randomized trial to date comparing Taxus and Cypher drug-eluting ...
While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the ...
The Certification Commission for Healthcare Information Technology is inviting organizations to submit their ambulatory ...
A subset analysis of diabetic patients in the SPIRIT II Clinical trial of the XIENCE V Everolimus Eluting Stent System ...
Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the ...
A stent designed to dissolve after it completes its task of propping open narrowed heart arteries is being tested ...
When it comes to opening blocked carotid arteries, surgery may be less risky than stents according to a study by ...
Boston Scientific has European CE clearance to begin marketing a private-label XIENCE V everolimus-eluting coronary ...
An FDA-appointed advisory panel to review drug-eluting stents could have detrimental effects on the $6 billion-a-year ...
Abbott Vascular says it will begin launching its XIENCE V stent system immediately in most European countries, focusing ...
Cordis Corp. has launched the CYPHER SELECT Plus Stent, the first third-generation DES, in Western and Eastern Europe ...
Positive six-month results of Abbott's SPIRIT II clinical trial of the XIENCE V Everolimus Eluting Coronary Stent ...
Plus, underuse of aspirin after stent is “a travesty” says Mayo doctor
Cardiologists were urged to halt the ...
The long-standing standard of care for patients with carotid artery disease was surgery and/or medical management ...